Amendments to the Claims

Please amend Claims 49, 88 and 140. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-48. (Cancelled)

49. (Currently Amended) A compound represented by the following Structural Formula:



or a stereoisomer [[,]] or a pharmaceutically acceptable salt ~~, solvate or hydrate thereof~~, wherein:

(a) T1 is selected from the group consisting of



;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl,

C_1-C_6 alkyl-COOR12, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryloxy, aryl-C_{0-4}-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is O;

(f) U is $-CH_2-$;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A and wherein

(i) A is selected from the group consisting of carboxyl, tetrazole, C_1-C_6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, acylsulfonamide and tetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl-C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is O;

(j) Z12 is selected from the group consisting of hydrogen and $-Z_{13}C_0$–C_3alkylZ_{14};

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, $CONZ_{15}$, and SO_2;

(l) Z_{14} is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z_{14}';

(m) Z_{15} is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z_{15}';

(n) R_9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl-C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl-C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R_{10}, R_{11} are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12'', C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, C3-C6 cycloalkylaryl-C_{0-2}-alkyl, aryloxy, C(O)R13', COOR14', OC(O)R15', $OS(O)_2R16'$, $N(R17')_2$, NR18'C(O)R19', $NR20'SO_2R21'$, SR22', S(O)R23', $S(O)_2R24'$, and $S(O)_2N(R25')_2$; and wherein aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three independently selected from R28;

(p) R12', R12'', R13', R14', R15', R16', R17', R18', R19', R20', R21', R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, and wherein C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-

C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

(s) R33 is selected from the group consisting of phenyl, thiophene, pyridine, piperidine,  , , and  , wherein the phenyl, thiophene, pyridine, piperidine,  ,  , and  , are each optionally substituted with R_{10} and R_{11}.

50. (Previously Presented) The compound of Claim 49, wherein the compound is represented by the following Structural Formula:



51. (Previously Presented) The compound of Claim 50, wherein the compound is represented by the following Structural Formula:



52-63. (Cancelled)

64. (Previously Presented) The compound of Claim 51, wherein the compound is represented by the following Structural Formula:



65-66. (Cancelled)

67. (Previously Presented) The compound of Claim 64, wherein:

E is C(R3)(R4)-COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl; and

R2 is a bond.

68-87. (Cancelled)

88. (Currently Amended) The compound of Claim 49 wherein the compound is selected from the group consisting of:

{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

[5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;

{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;

{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[3-(4-Butyl-phenoxy)-propoxy]-indol-1-yl}-acetic acid;

(5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-propionic acid;

2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide; and

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-benzenesulfonamide ~~; and~~ .

89-91. (Cancelled)

92. (Previously Presented) A method of treating a mammal in need of treatment for a disease selected from the group consisting of diabetes mellitus, Syndrome X, and atherosclerosis, comprising the step of administering to the mammal in need thereof a therapeutically effective amount of the compound of Claim 49.

93-94. (Cancelled)

95. (Previously Presented) The method of Claim 92, wherein the disease is diabetes mellitus.

96. (Previously Presented) The method of Claim 92, wherein the disease is Syndrome X.

97-139. (Cancelled)

140. (Currently Amended) The compound of Claim 49, wherein the compound is selected from the group consisting of:
{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
[5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;
{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
{5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;
{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;
3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-propionic acid;
{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
(5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
{5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
(5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;
3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
(S)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
(R)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-propionic acid;
2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide; and

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-benzenesulfonamide ~~; and~~ .